During the last session, Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX)’s traded shares were 83028.0, with the beta value of the company hitting 1.03. At the end of the trading day, the stock’s price was $1.43, reflecting an intraday loss of -2.05% or -$0.03. The 52-week high for the BDRX share is $74.00, that puts it down -5074.83 from that peak though still a striking 20.28% gain since the share price plummeted to a 52-week low of $1.14. The company’s market capitalization is $0.96M, and the average intraday trading volume over the past 10 days was 2.24 million shares, and the average trade volume was 1.90 million shares over the past three months.
Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX) trade information
Biodexa Pharmaceuticals Plc ADR (BDRX) registered a -2.05% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.05% in intraday trading to $1.43, hitting a weekly high. The stock’s 5-day price performance is -8.92%, and it has moved by -38.89% in 30 days. Based on these gigs, the overall price performance for the year is -93.35%. The short interest in Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX) is 68470.0 shares and it means that shorts have 0.02 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 83.98%.
BDRX Dividends
Biodexa Pharmaceuticals Plc ADR is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX)’s Major holders
Biodexa Pharmaceuticals Plc ADR insiders own 2.30% of total outstanding shares while institutional holders control 7.85%, with the float percentage being 8.04%.
Data provided on Feb 28, 2025 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 78.0 shares. This amounts to just over 0.00 percent of the company’s overall shares, with a $111.0 market value.
